A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)
Status:
Completed
Trial end date:
2015-12-23
Target enrollment:
Participant gender:
Summary
This study will evaluate safety, pharmacokinetics (PK), and the ability of MK-1075 to
suppress viral load (VL) in HCV-infected participants during 7 days of once daily dose
administration. The primary hypothesis is at a once-daily dose that is sufficiently safe and
well tolerated in HCV-infected participants, the mean maximum HCV RNA (log10 IU/mL) reduction
is at least 3 log10 IU/mL as compared to baseline following multiple dose oral administration
of MK-1075 in HCV genotype 1 (GT1) and genotype 3 (GT3) infected participants.